

Date: 30/05/2024
Your Ref:
Our Ref: 8764

Enquiries to : Richard Mutch
Extension: 35687
Direct Line: 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – RHEUMATOLOGY

I write in response to your request for information in relation to rheumatology prescribing.

Question:

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- a) Abatacept [Orencia]
- b) Adalimumab [Humira]
- c) Adalimumab Biosimilars
- d) Apremilast [Otezla]
- e) Baricitinib [Olumiant]
- f) Bimekizumab [Bimzelx]
- g) Certolizumab [Cimzia]
- h) Etanercept [Enbrel]
- i) Etanercept Biosimilars
- j) Filgotinib [Jyseleca]
- k) Golimumab [Simponi]
- l) Guselkumab [Tremfya]
- m) Infliximab [Remicade]
- n) Infliximab Biosimilars
- o) Ixekizumab [Taltz]
- p) Risankizumab [Skyrizi]
- q) Rituximab [MabThera]
- r) Rituximab Biosimilars
- s) Sarilumab [Kevzara]
- t) Secukinumab [Cosentyx]
- u) Tocilizumab [Ro Actemra]
- v) Tocilizumab Biosimilars
- w) Tofacitinib [Xeljanz]
- x) Upadacitinib [Rinvoq]
- y) Ustekinumab [Stelara]

Answer:

Below is the information requested with the following limitations:

1. Our database cannot give dates of treatment so the data below is a snapshot of current patients from w/c 29th April.
2. Diagnosis is input by non-clinical staff and therefore may not be 100% accurate
3. Infusions are not recorded through the database so missing data on rituximab patients as well as IV infusions of tocilizumab, infliximab, abatacept.

All diagnoses

Abatacept	70
Adalimumab	5<
Amgevita	605
Anakinra	23
Apremilast	13
Baricitinib	145
Belimumab	13
Benepali	540
Bimekizumab	6
Burosumab	5<
Canakinumab	5<
Certolizumab	249
Enbrel	30
Erelzi	206
Filgotinib	292
Golimumab	12
Guselkumab	9
Humira	48
Imraldi	466
Infliximab	11
Ixekizumab	11
Ofatumumab	5<
Remsima	5<
Sarilumab	58
Secukinumab	269
RoActemra	9
Tofacitinib	29
Tyenne	177
Upadacitinib	210
Ustekinumab	5<

Question:

2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

- a) Abatacept [Orencia]
- b) Adalimumab [Humira]
- c) Adalimumab Biosimilars
- d) Apremilast [Otezla]
- e) Bimekizumab [Bimzelx]
- f) Certolizumab [Cimzia]
- g) Etanercept [Enbrel]
- h) Etanercept Biosimilars
- i) Golimumab [Simponi]
- j) Guselkumab [Tremfya]
- k) Infliximab [Remicade]
- l) Infliximab Biosimilars
- m) Ixekizumab [Taltz]
- n) Risankizumab [Skyrizi]
- o) Secukinumab [Cosentyx]
- p) Tofacitinib [Xeljanz]
- q) Upadacitinib [Rinvoq]
- r) Ustekinumab [Stelara]

Answer:

PsA diagnosis

Adalimumab	5<
Amgevita	160
Apremilast	10
Benepali	95
Bimekizumab	5<
Certolizumab	52
Enbrel	10
Erelzi	50
Golimumab	5<
Guselkumab	8
Humira	10
Imraldi	125
Infliximab	5<
Ixekizumab	10
Remsima	5<
Secukinumab	147

Tofacitinib	14
Upadacitinib	67
Upadicitinib	5<
Ustekinumab	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing, Midwifery and AHPs
Cc: Chief Executive